Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2014
05/08/2014WO2014069655A1 Immune-tolerance inducer
05/08/2014WO2014069626A1 Method for producing pyrimidodiazepinone compound
05/08/2014WO2014069615A1 Retinoic acid microneedle
05/08/2014WO2014069566A1 External composition for skin
05/08/2014WO2014069555A1 Propyl-phenyl-ether derivative and melanogenesis inhibitor, skin-lightening agent, antimicrobial agent, and cosmetic containing said propyl-phenyl-ether derivative
05/08/2014WO2014069554A1 Quinuclidine amide derivative and medicinal use of same
05/08/2014WO2014069523A1 Carnosadine lactam derivative having antibacterial activity
05/08/2014WO2014069510A1 Novel amine derivative or salt thereof
05/08/2014WO2014069434A1 Novel thiazolidinone derivative
05/08/2014WO2014069426A1 Benzimidazole having ampk activating effect and azabenzimidazole derivative
05/08/2014WO2014069401A1 Pulmonary disease-specific therapeutic agent
05/08/2014WO2014069255A1 Anticancer agent, and combination use anticancer agent
05/08/2014WO2014069227A1 Metabolism-improving agent comprising rare fatty acid
05/08/2014WO2014068988A1 Pyrazolopyridine derivatives as ttx-s blockers
05/08/2014WO2014068972A1 Side effect reducing agent for sorafenib
05/08/2014WO2014068698A1 Lipid droplet and cellulite inhibiting device
05/08/2014WO2014068600A1 Stable transdermal pharmaceutical drug delivery system comprising diclofenac
05/08/2014WO2014068585A1 Novel lyophilized compositions of cyclophosphamide
05/08/2014WO2014068553A1 Aptamers, multimeric aptamers and uses thereof
05/08/2014WO2014068542A1 Novel targets in multiple myeloma and other disorders
05/08/2014WO2014068527A1 Bruton's tyrosine kinase inhibitors
05/08/2014WO2014068514A1 Cancer treatment methods
05/08/2014WO2014068507A1 Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants
05/08/2014WO2014068506A2 Compositions and methods for the treatment of autoimmune diseases
05/08/2014WO2014068463A2 Compositions and methods for the treatment of inflammation and metabolic disorders
05/08/2014WO2014068461A2 Compositions and methods for the treatment of acute inflammation
05/08/2014WO2014068460A2 Compositions and methods for the treatment of neurologic diseases and neurological disorders
05/08/2014WO2014068459A2 Compositions and methods for the treatment of pain and neurological diseases
05/08/2014WO2014068397A1 Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
05/08/2014WO2014068388A1 2 substituted cephem compounds
05/08/2014WO2014068372A1 Pharmaceutical composition of tapentadol for parenteral administration
05/08/2014WO2014068327A2 Agents for the prevention and/or treatment of central nervous system damage
05/08/2014WO2014068320A1 Ketone body inhibitors for use in the treatment of gastrointestinal tract mucosa impairment
05/08/2014WO2014068296A1 Fat loss composition
05/08/2014WO2014068265A1 Antiviral phosphonate analogues and process for preparation thereof
05/08/2014WO2014068171A1 N-substituted 4-aminophenols and corresponding quinone imines
05/08/2014WO2014068104A1 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use as soluble guanylate cyclase stimulants
05/08/2014WO2014068099A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
05/08/2014WO2014068095A1 Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use as soluble guanylate cyclase stimulants
05/08/2014WO2014068070A1 Methods for preventing antiphospholipid syndrome (aps)
05/08/2014WO2014068035A1 Novel rock inhibitors
05/08/2014WO2014068007A1 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
05/08/2014WO2014067986A1 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
05/08/2014WO2014067985A1 Compounds for use in the treatment of parasitic diseases
05/08/2014WO2014067960A2 Functionalized 9-bromo-camptothecin derivatives
05/08/2014WO2014067904A1 New antibacterial compounds and biological applications thereof
05/08/2014WO2014067861A1 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
05/08/2014WO2014067699A1 Administration of aerosolised iloprost
05/08/2014WO2014067610A1 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
05/08/2014WO2014067501A1 Dispersible tablets containing deferasirox
05/08/2014WO2014067499A1 Stabilization of tiotropium solvates
05/08/2014WO2014067473A1 N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof
05/08/2014WO2014067417A1 Novel quinoline compound and use thereof
05/08/2014WO2014067379A1 Deuterated dimethyl amine parthenolide, preparation method and use thereof in drug preparation
05/08/2014WO2014067336A1 Anti-tumor bivalent platinum complex and preparation method for complex and ligand of complex
05/08/2014WO2014067281A1 Tapentadol hydrochloride crystalline form c and preparation method and use thereof
05/08/2014WO2014067008A1 Therapy for constipation
05/08/2014WO2014067003A1 Glycosidase inhibitors and uses thereof
05/08/2014WO2014067002A1 Synthetic lethality and the treatment of cancer
05/08/2014WO2014066967A1 Ingenol-derived compounds that can be used for treating cancer
05/08/2014WO2014066944A1 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
05/08/2014WO2014043110A3 Crosslinked polymer nano-assemblies and uses thereof
05/08/2014WO2014042433A3 Compounds and compositions for modulating adenosine a3 receptor activity
05/08/2014WO2014041565A3 Improved process for preparation of vilanterol and intermediates thereof
05/08/2014WO2014041517A3 Dendrimers, conjugates and methods thereof
05/08/2014WO2014041489A3 Rapidly dissolving pharmaceutical composition
05/08/2014WO2014041446A3 Compositions and methods for treatment of metabolic diseases
05/08/2014WO2014041445A3 Compounds and compositions for treatment of hypertension and management of diabetic kidney disease
05/08/2014WO2014038881A3 Protein kinase inhibitor comprising pyridine derivatives
05/08/2014WO2014028589A3 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
05/08/2014WO2014025785A3 Prion protein ligands as therapeutic agents for neurodegenerative disorders
05/08/2014WO2014000629A9 Hexahydropentaleno derivatives, preparation method and use in medicine thereof
05/08/2014WO2013186493A3 Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt
05/08/2014WO2013142654A3 Compositions for delivering perfume to the skin
05/08/2014WO2013138628A3 Injectable ibuprofen formulation
05/08/2014WO2013092424A3 Active ingredient combinations comprising one or more polyols and one or more physiologically harmless hydroxamic acids, and cosmetic or dermatological preparations containing such active substance combinations
05/08/2014WO2013066481A3 Cosmetic use of n-heteroarylbisamide analogs and related compounds
05/08/2014WO2013062670A3 New routes to trans a,b-substituted bacteriochlorins
05/08/2014WO2013033602A3 Fatty acid amides, compositions and methods of use
05/08/2014WO2013029060A3 Compositions and methods for treating neurodegenerative disease
05/08/2014WO2013028267A3 Cosmetic use of substituted amino heterocyclic carbamoyl analogs and related compounds
05/08/2014WO2013019945A3 Method for selection of chemotherapeutic agents for adenocarcinoma cancer
05/08/2014WO2013006230A3 Combined inhibition of the vitamin d receptor and dna replication in the treatment of cancer
05/08/2014WO2013003689A3 Compositions containing nitro fatty acids
05/08/2014WO2012178208A3 Selective inhibitors of histone deacetylase isoform 6 and methods thereof
05/08/2014WO2012171015A3 Therapeutic combination for cancer treatment
05/08/2014WO2012167092A3 Uses of and methods of treatment with cystathionine
05/08/2014WO2012162439A3 Compositions comprising fusidic acid and packages therefor
05/08/2014WO2012158957A3 Kinase modulation and indications therefor
05/08/2014WO2012154879A3 Autophagy inhibitors
05/08/2014WO2012149349A3 Prophylaxis and treatment of enteropathogenic bacterial infection
05/08/2014WO2006135362A9 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
05/08/2014US20140128633 Compositions containing nitro fatty acids
05/08/2014US20140128606 Antipruritic agent
05/08/2014US20140128591 Antisense design
05/08/2014US20140128590 Hydrolases, nucleic acids encoding them and methods for making and using them
05/08/2014US20140128586 Amino-lna, thio-lna and alpha-l-oxy-ln
05/08/2014US20140128585 Fructose absorption inhibitor
05/08/2014US20140128552 Compositions suitable for use in personal care products comprising crosslinked polymers containing biomass derived materials
05/08/2014US20140128475 Agent for the prevention, improvement or treatment of retinal disease
1 ... 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 ... 7860